

# Review of: "[Review Article] Pitavastatin: A Comprehensive Overview of its Mechanisms, Pharmacokinetics, Pharmacodynamics, and Adverse Effects"

Ahmed Shawky Elserafy<sup>1</sup>

<sup>1</sup> Ain Shams University

Potential competing interests: No potential competing interests to declare.

The review is very interesting. However, there are some points to be revised:

1. There is no mention of the dyslipidemia guidelines, whether ESC or ACC/AHA. It is important to include them as they are the largest bodies discussing lipid management in different patient subsets.
2. Mentioning the elevation of HDL as a target has been given a class III recommendation in guidelines and thus should not be a target in lipid management.
3. Comparing pitavastatin and atorvastatin in efficacy is not absolutely correct, as atorvastatin in the 40 and 80 mg doses is considered a high-intensity statin, while pitavastatin in the 4 mg dose is considered moderate intensity. Also, the clinical data for atorvastatin and simvastatin is huge as compared to pitavastatin.
4. No mention of the frequently discussed lower rates of statin-associated muscle symptoms with pitavastatin as compared to other statins.
5. CKD is not a side effect. It is a comorbidity.